Cargando...
Golimumab pharmacokinetics in ulcerative colitis: a literature review
Golimumab (GLM) is the latest anti-tumor necrosis factor (TNF) that gained its marketing license. Thanks to the PURSUIT induction and maintenance trials, it was approved for the treatment of ulcerative colitis (UC) in 2013. The other anti-TNF drugs available are infliximab and adalimumab. These two...
Guardado en:
| Publicado en: | Therap Adv Gastroenterol |
|---|---|
| Autores principales: | , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
SAGE Publications
2016
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5330616/ https://ncbi.nlm.nih.gov/pubmed/28286562 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X16676194 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|